

# Friday, October 28, 2022

# Virtual (Scan QR code to register for Virtual Friday Program)

## 7:30 am Opening Remarks - Philip Kerr, MD, President Elect

## 7:35 am The Future of Dermatology Panel

- Donna Aiudi, MD
- Frank Castiglione, MD
- Loyd Godwin, MD
- Steven Kolenik, MD
- Dennis Feinberg, MD
- David Leffel, MD
- Alicia Zalka, MD

Objective: To review various practice models, including pros & cons of each model.



## 8:05 am Approved and Pipeline Treatments for Areata

- Brett King, MD

Objectives: 1. Distinguish between the pathophysiology of alopecia areata and other causes of hair loss 2. Use clinical trial data on the efficacy, safety, and durability of JAK inhibitors to recognize patients with AA who may benefit from these therapies 3. Identify risk factors for disease progression and poor prognosis in patients with AA 4. Develop treatment regimens for patients with AA that consider the psychosocial burden of the disease and associated autoimmune disorders

8:35 am Join Pfizer: Learn About An Oral RX Treatment For Moderate-to-Severe Atopic Dermatitis - Sposored by

- Peter A. Lio, MD Clinical Assistant Professor of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine Founding Director, Chicago Integrative Eczema Center, Founding Partner, Medical Dermatology Associates of Chicago, Chicago, IL

## 9:15 am Infectious Disease: 2022 Update

- Ted Rosen, MD, Professor and Vice-Chair of Dermatology and Chief of Dermatology at the Houston Veterans Affairs Medical Center Objectives: 1. Integrate newest anti-infective agents into clinical practice 2. Understand current status of Covid-19 pandemic 3. Become aware of other developing epidemics/potential pandemics.

# 9:45 am Rinvoq for Atopic Dermatitis - Sposored by

- Bruce Strober, MD

Objectives: 1. Understand the burden of AD. 2. Discuss the efficacy and safety of RINVOQ in patients with moderate to severe AD. 3. Review resources available through RINVOQ Complete.

## 10:30 am Contact Dermatitis

- David E. Cohen MD, MPH - Charles C. and Dorothea E. Harris Professor and Executive Vice Chairman for Operations and Strategy, The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine Objectives: 1.Identify trends in the prevalence of contact allergens. 2.Review common presentations for emerging allergens in contact dermatitis. 3.Review common locations and strategies for avoiding contact allergens.

#### 11:00 am Certificates and Door Prizes

This activity has been planned and implemented in accordance with the Essentials and Standards of the Connecticut State Medical Society through the joint sponsorship of CSEP and The Connecticut Dermatology & Dermatologic Surgery Society. CSEP is accredited by the CSMS to provide continuing medical education for physicians.

CSEP designates this educational activity for a maximum of 1.5 AMA PRA Category I Credit(s)™ toward the AMA Physicians Recognition Award. Each physician should claim only those hours of credit that he/she spent in the activity.











# **Brett King, MD**

Dr. King is Associate Professor of Yale Dermatology, specializing in skin diseases recalcitrant to first-line therapies. He has pioneered the use of Janus kinase (JAK) inhibitors in cutaneous diseases, in particular for alopecia areata, vitiligo, atopic dermatitis, granuloma annulare, sarcoidosis, and erosive lichen planus, in addition to other disorders. Dr. King received his B.A. at the University of California at Santa Cruz, his Ph.D. from Stanford University and his M.D. from Yale University School of Medicine. He completed medical internship at Massachusetts General Hospital and dermatology residency and fellowship at Yale University School of Medicine.

Dr. King is an investigator in numerous clinical trials. He lectures nationally and internationally and publishes extensively.



# TED ROSEN, MD

Dr. Rosen is a native of Chicago. After attending Michigan State University as a National Merit Scholar, Dr. Rosen graduated from the University of Michigan Medical School cum laude. He trained in internal medicine at the University of Alabama and in dermatology at Baylor College of Medicine, where he currently serves as Professor and Vice-Chair of Dermatology and Chief of Dermatology at the Houston Veterans Affairs Medical Center. Dr. Rosen previously served a term on the Board of Directors and is a past Vice-President of the American Academy of Dermatology. He is a past Vice-President of Texas Dermatological Society, a past-President and Secretary-Treasurer of the Houston Dermatological Society and prior Chairman and Secretary-Treasurer of the Dermatology Section, Southern Medical Association. Dr. Rosen was the 2017 recipient of the AAD Thomas G. Pearson Memorial Award for lifelong achievement in education, the 2019 recipient of Baylor's prestigious Master Clinician award, and the 2021 recipient of the Robert J Freeman Memorial Mentoring and Leadership Award from the Texas Dermatology Society. Dr. Rosen has written over 350 peer-reviewed journal articles, 28 textbook chapters and 4 textbooks. He has been a visiting professor at over 75 university training programs and a plenary speaker for many city, state, national and international organizations, including the national dermatology societies of Canada, Mexico, Argentina, Chile, Hong Kong, Taiwan, Korea, China, Italy, Australia and New Zealand. He has also been a plenary speaker at the World Congress of Dermatology, Congress of Ibero-Latin American Dermatologists and the European Academy of Dermatology and Venereology. On a personal note, he is most proud of his role helping to raise four, productive, sane and debt-free adult children. Dr. Rosen is an avid numismatist, diehard Chicago Cub fan and life-long devotee of horror films.



# David E. Cohen, MD, MPH

Dr. Cohen, is currently Associate Professor of Dermatology, Vice Chairman of Clinical Affairs, and Director, Occupational and Environmental Dermatology and Chief of Allergy and Contact Dermatitis in the Department of Dermatology at the New York University School of Medicine. He is also lecturer of Environmental Sciences in the Columbia University School of Public Health.

An acknowledged expert on contact dermatitis, Dr. Cohen has served as President of the American Contact Dermatitis Society which is the Pan American organization focused on improving the care of patients with occupational, environmental and allergic diseases of the skin. He is a founding board member of the American Acne and Rosacea society, and has served as President of the Dermatology Section for the New York Academy of Medicine, as Chairman of several committees of the American Academy of Dermatology, on the committee that set guidelines of care for the American College of Allergy, Asthma, and Immunology. He serves on the National Academy of Science-Institute of Medicine's Committee to Review the Federal Response to the Health Effects Associated with the Gulf of Mexico Oil Spill. He is also studying and developing a bioterrorism preparedness plan for cutaneous anthrax for the Centers for Disease Control and Prevention (CDC). He serves as a clinical consultant to numerous companies.

Dr. Cohen has published widely in the field of clinical dermatology and is a frequent lecturer at national and international meetings. He was recently Program Chairman for the 130th Annual Meeting of the American Dermatological Association. Dr. Cohen is a member of the editorial board of Journal of Drugs in Dermatology and the editorial advisory boards of Dermatitis and Skin and Allergy News.

A Summa Cum Laude graduate of City University of New York, Dr. Cohen received his medical degree from the State University of New York at Stony Brook School of Medicine in Stony Brook, New York, and earned a Master of Public Health from the Columbia University School of Public Health in New York. He has been honored by election to Alpha Omega Alpha, the medical honor society, has received the Merck Sharp Dohme Award for Academic Excellence.

# Connecticut Dermatology Society Financial Interest Disclosure Report October 27 & 28, 2022

# Speaker

### **Financial Interest Received**

David E. Cohen, MD, MPH

Ferndale Laboratories, Asana, Leo, UCB, Novartis, Dermavant, SFJ, FIDE. (FIDE receives industry sponsorship from AbbVie, Arena Pharma, Arcutis, Inctye, Janssen, LEO Pharma, Pfizer, Sanofi Regeneron, Sun Pharma, UCB), Cosmetic Ingredient Review (CIR)—Consultant and Honorarium; Dermira [past], Medimetriks [past], Brickell Biotech [past], Kadmon [past], Evommune, Timber—Stock or stock options; Timber, Evommune, [Dermira-Past-Lilly], [Kadmon-Past-Sanofi]—Board of Directors:

Jeff Gehlhausen, MD

None

Omar Ibrahimi, MD, PhD

AbbVie, Accure Acne, Cutera, Lutronic, Blueberry Therapeutics, Organogenesis – *Advisory Board*; AbbVie, Johnson & Johnson, Candesant, Cutera, Procter & Gamble, Unilever, Editas, Crisper Therapeutics, Intellia, Moderna, Beam Therapeutics, Pfizer, Revance, General Electric, Anthem, Viatris, Vertex Phamaceuticals, Vivene, Regeneron, AVAVA Medical, Accure Acne, Ginkgo Bioworks Holdings, Blueberry Therapeutics, Quthero – *Stockholder*; American Society for Dermatologic Surgery, American Society for Lasers in Surgery and Medicine, Blueberry Therapeutics (Observer)

Brett King, MD

Jun Lu, MD

Regeneron-Investigator

Ted Rosen, MD

Financial disclosure forms available upon request.